← Back

Wire · opportunities

Experimental Pan-KRAS Pill Plus Cetuximab Shrank Tumors in 5 of 16 Advanced Colorectal ...

Published

21 November 2026

Topic

opportunities

◆ Sectors

BiotechDrug Discovery

◆ Source

Read at medicaldaily.com →

◆ Verified

Fusion42 · 22 November 2026 · Fusion42 review

An experimental pan-KRAS inhibitor pill, ALTA3263, combined with cetuximab, showed tumor shrinkage in 31% of advanced colorectal cancer patients in an early Phase 1 trial, addressing multiple KRAS mutations beyond the limited G12C target of existing drugs.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.

◆ ◆ The Wire takeaway

You now have a new drug in testing that could open colorectal cancer patients with hard-to-treat KRAS mutations. Testing combinations beyond G12C mutations can shift treatment options in a tough biotech niche.

◆ Coverage

1 source · 21 Nov 2026

◆ Related on Wire

◆ Topics

BiotechDrug Discoverykras-mutationcolorectal-cancerearly-trialpan-kras-inhibitorcetuximab-combo